SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Sumitomo Pharma Co., Ltd. (DNPUF) 当前追踪市盈率 (P/E) 为 0.2, 前瞻市盈率为 0.0. 追踪盈利收益率为 526.32%, 前瞻盈利收益率 2,500.00%.
本页证实的标准:
- VALUE (100/100, 通过) — 市盈率低于市场平均水平 (0.2); 盈利收益率超过债券收益率 (526.32%).
- 前瞻市盈率 0.0 (低于追踪值 0.2) — 分析师预计盈利将增长，这将改善估值。
- 追踪盈利收益率 526.32% — 超过典型债券收益率（约4.3%），使股票相对固定收益更具吸引力。 前瞻收益率改善至 2,500.00% 随着盈利恢复。
SharesGrow 综合评分： 45/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✗
健康
17/100
Debt-to-Equity & liquidity
→ Health
估值概览 — DNPUF
估值倍数
P/E (TTM)0.2
前瞻 P/E0.0
PEG 比率N/A
前瞻 PEG0.00
P/B 比率0.00
P/S 比率0.01
EV/EBITDA0.0
每股数据
EPS (TTM)$59.49
前瞻 EPS（预估）$260.58
每股账面价值$0.00
每股营收$1,003.88
每股自由现金流$0.00
收益率与内在价值
盈利收益率526.32%
Forward Earnings Yield2,500.00%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$62.16 |
$403.21B |
$24.7B |
6.1% |
| 2017 |
$78.82 |
$411.65B |
$31.32B |
7.6% |
| 2018 |
$134.53 |
$466.84B |
$53.45B |
11.4% |
| 2019 |
$122.39 |
$459.27B |
$48.63B |
10.6% |
| 2020 |
$102.58 |
$482.73B |
$40.75B |
8.4% |
| 2021 |
$141.50 |
$515.95B |
$56.22B |
10.9% |
| 2022 |
$141.99 |
$560.04B |
$56.41B |
10.1% |
| 2023 |
$-187.55 |
$555.54B |
$-74.51B |
-13.4% |
| 2024 |
$-792.79 |
$314.56B |
$-314.97B |
-100.1% |
| 2025 |
$59.49 |
$398.83B |
$23.63B |
5.9% |
